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Maternal colonization with Streptococcus
agalactiae and associated stillbirth and neonatal
disease in coastal Kenya
Anna C. Seale1,2*, Angela C. Koech2, Anna E. Sheppard3, Hellen C. Barsosio2, Joyce Langat2,
Emily Anyango2, Stella Mwakio2, Salim Mwarumba2, Susan C. Morpeth2,4, Kirimi Anampiu2,
Alison Vaughan3, Adam Giess3, Polycarp Mogeni2, Leahbell Walusuna2, Hope Mwangudzah2,
Doris Mwanzui5, Mariam Salim5, Bryn Kemp2,6, Caroline Jones1,2,4, Neema Mturi2, Benjamin Tsofa2,
Edward Mumbo7, David Mulewa7, Victor Bandika8, Musimbi Soita9, Maureen Owiti5, Norris Onzere5,
A. Sarah Walker3, Stephanie J. Schrag10, Stephen H. Kennedy6, Greg Fegan1,2, Derrick W. Crook3
and James A. Berkley1,2
Streptococcus agalactiae (group B streptococcus, GBS) causes neonatal disease and stillbirth, but its burden in
sub-Saharan Africa is uncertain. We assessed maternal recto–vaginal GBS colonization (7,967 women), stillbirth and
neonatal disease. Whole-genome sequencing was used to determine serotypes, sequence types and phylogeny. We found
low maternal GBS colonization prevalence (934/7,967, 12%), but comparatively high incidence of GBS-associated stillbirth
and early onset neonatal disease (EOD) in hospital (0.91 (0.25–2.3)/1,000 births and 0.76 (0.25–1.77)/1,000 live births,
respectively). However, using a population denominator, EOD incidence was considerably reduced (0.13 (0.07–0.21)/
1,000 live births). Treated cases of EOD had very high case fatality (17/36, 47%), especially within 24 h of birth, making
under-ascertainment of community-born cases highly likely, both here and in similar facility-based studies. Maternal GBS
colonization was less common in women with low socio-economic status, HIV infection and undernutrition, but when
GBS-colonized, they were more probably colonized by the most virulent clone, CC17. CC17 accounted for 267/915 (29%)
of maternal colonizing (265/267 (99%) serotype III; 2/267 (0.7%) serotype IV) and 51/73 (70%) of neonatal disease
cases (all serotype III). Trivalent (Ia/II/III) and pentavalent (Ia/Ib/II/III/V) vaccines would cover 71/73 (97%) and 72/73
(99%) of disease-causing serotypes, respectively. Serotype IV should be considered for inclusion, with evidence of
capsular switching in CC17 strains.
One-half of all child deaths (<5 years) worldwide are in sub-Saharan Africa (sSA)1 and one-third of these deaths occurin the neonatal period, from infection, preterm birth and
neonatal encephalopathy1. Stillbirths probably equal neonatal
deaths in number, and infections are a major contributor2.
Streptococcus agalactiae (group B streptococcus, GBS) causes neo-
natal early and late onset disease (EOD, LOD), stillbirth3 and poss-
ibly contributes to preterm birth4 and neonatal encephalopathy5, as
a consequence of ascending maternal genito-urinary colonization
(for deﬁnitions see Supplementary Table 1). GBS emerged as the
leading cause of EOD in the USA in the 1960s6 and subsequently
in Europe, but in sSA there are outstanding major questions as to
whether GBS commonly colonizes pregnant women, causes still-
birth, or is an important cause of neonatal disease. Establishing
this is essential to informing potential preventive interventions. In
resource-rich countries, reductions in EOD have followed the intro-
duction of maternal microbiological or risk factor screening with
intra-partum antibiotic prophylaxis (IAP)7. However, there is
uncertainty as to the feasibility of this approach in resource-poor
settings, and there is no evidence of the effectiveness of IAP in
preventing GBS-associated stillbirth, or LOD. Antisepsis at delivery
has been shown to be ineffective8. However, maternal vaccination
may provide a feasible strategy to reduce GBS disease in resource-
poor countries. A trivalent conjugate vaccine (serotypes Ia/Ib/III)
has completed phase 2 clinical trials9, and a pentavalent vaccine
is in development10.
Understanding which women are most likely to be GBS colo-
nized could provide insight into both the emergence of GBS and
variation in the reported prevalence of maternal GBS colonization:
Europe/USA 5–40% (refs 11,12); Africa 9–47% (Supplementary
Table 2). Reported maternal risk factors for colonization are con-
ﬂicting, with increased maternal GBS colonization reported in
both younger13 and older14 age groups, African-American
mothers13–15 and those with higher education14,16, higher income16,
1Nufﬁeld Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford OX3 7FZ, UK. 2KEMRI-Wellcome Trust
Research Programme, Kiliﬁ 80108, Kenya. 3Modernizing Medical Microbiology Consortium, Nufﬁeld Department of Medicine, University of Oxford, Oxford
OX3 9DU, UK. 4London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 5Maternity Department, Kiliﬁ County Hospital,
Main Hospital Road, Kiliﬁ 80108, Kenya. 6Nufﬁeld Department of Obstetrics and Gynaecology, University of Oxford, Oxford, OX3 9DU, UK. 7County
Ministry of Health, Kiliﬁ County Hospital, Main Hospital Road, Kiliﬁ 80108, Kenya. 8Department of Paediatrics, Coast Provincial General Hospital, Mombasa
80100, Kenya. 9Department of Obstetrics and Gynaecology, Coast Provincial General Hospital, Mombasa 80100, Kenya. 10Division of Bacterial Diseases,
Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, Georgia, 30333, USA. *e-mail: anna.seale@gmail.com
ARTICLES
PUBLISHED: 23 MAY 2016 | ARTICLE NUMBER: 16067 | DOI: 10.1038/NMICROBIOL.2016.67
NATURE MICROBIOLOGY | VOL 1 | JULY 2016 | www.nature.com/naturemicrobiology 1
© 2016 Macmillan Publishers Limited. All rights reserved
high sexual activity14 and obesity15,16. Data from sSA are limited, but
are also conﬂicting for potentially important risk factors such as
HIV infection. In South Africa, maternal GBS colonization was
lower in HIV-infected mothers17, but in Malawi, only amongst
HIV-infected mothers with lower CD4 counts18. In the USA15 and
Zimbabwe19, no association with HIV was found. The limited
data from studies in Kenya, Zimbabwe, Malawi and South Africa
on colonizing maternal serotypes in sSA suggest serotype III is the
most common (serotypes Ia/Ib/II/IV/V are also reported)18,20–22.
For neonatal disease, data outside the USA and Europe are
sparse23. In sSA, facility-based studies generally report a high inci-
dence of neonatal GBS disease, but population-based and outpatient
studies have reported much lower incidences24,25, including what
was described as a ‘striking absence’ of invasive neonatal GBS
disease in large outpatient-based studies24. However, regional esti-
mates, which included only four studies from Africa (one of
which is our study site in Kiliﬁ County)8,26–28, suggest that Africa
may have the highest regional burden of neonatal GBS disease at
1.2 (0.50–1.91)/1,000 live births23. These limited data suggest that
serotype III, as described in other regions23, most commonly causes
disease, with rates for EOD and LOD of 52 and 72% in Malawi and
49 and 76% in South Africa; serotypes Ia/Ib/II/V are also reported27,29.
The incidence of GBS-associated stillbirth is unknown in sSA3,
with data from only two studies (one found no GBS-associated still-
birth30, and the other reported GBS-associated stillbirth in 8/66
(12%) stillbirths31).
The population structure of GBS in Europe and the USA can be
described by ﬁve major clonal complexes: CC1, CC10, CC17, CC19
and CC23 (refs 32,33), with CC17 overrepresented in disease
isolates32,34. These ﬁve clonal complexes are also found in Africa32.
In addition, CC26 is common in some regions, representing 15%
of sampled GBS isolates in Dakar and Bangui35. GBS also causes
bovine mastitis, which is largely mediated by the bovine-speciﬁc
CC67, although the ﬁve major human clonal complexes can also
be found in cattle33,36,37.
In this study, we aimed to comprehensively describe the clinical
epidemiology of maternal GBS colonization, neonatal disease and
stillbirth in coastal Kenya, with molecular analysis to determine
the associated serotypes, sequence types (STs) and phylogeny.
Results
Maternal GBS colonization and adverse perinatal outcomes.
During the study, 10,130 pregnant women attended a health
facility and we recruited 7,967 (Fig. 1, sample size Supplementary
Table 3). Of these, 526/7,967 (6.6%) were from rural sites, 5,470/
7,967 (68.7%) were from semi-rural locations and 1,971/7,967
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Figure 1 | Study design and recruitment of participants by study site. a, Recruitment timeline and sub-studies undertaken at each study site. b, Recruitment
of mothers into the cohort study. *The denominator for live births in the prospective cohort period, used to calculate incidence of early onset disease (EOD)
in KCH excluded those who did not deliver or had a stillbirth (leaving 6,598). **These mothers (7,967) were included in the analysis of risk factors for
maternal GBS colonization. §These births (7,833) were included in analyses assessing GBS as a risk factor for stillbirth or perinatal death. §§These live births
(7,408) were included in analyses assessing GBS as a risk factor for preterm birth, low birthweight or possible serious bacterial infection. c, Recruitment for
the vertical transmission study (maternal–neonatal dyads), a subset of mothers who delivered in KCH. d, Recruitment for stillbirth nested case–control study
including mothers who delivered in KCH and had a stillbirth, and controls.
ARTICLES NATURE MICROBIOLOGY DOI: 10.1038/NMICROBIOL.2016.67
NATURE MICROBIOLOGY | VOL 1 | JULY 2016 | www.nature.com/naturemicrobiology2
© 2016 Macmillan Publishers Limited. All rights reserved
(24.7%) were from an urban site. There were some differences in
demographics in those excluded (Supplementary Table 4), with
emergency referrals more likely to be excluded, as well as women
with incomplete data on age, ethnicity or parity, although overall
numbers were small. Transport times to the laboratory were
longer from urban and rural sites (median 11 h (range 0–48 h);
11 h (0–52 h)) compared to semi-rural locations (5 h (0–73 h),
but there was no evidence of association between GBS isolation
and time to sample processing across all sites (odds ratio (OR) =
1.00 (0.99–1.00), P = 0.6), across rural and urban sites (OR = 0.99
(0.98–1.00)), or each site individually (Supplementary Fig. 1).
Overall, 934 (11.7% (11.0–12.5%)) women were GBS-colonized
at delivery. Prevalence was lowest at rural sites (47/526, 8.9%
(6.6–11.7%)), intermediate at semi-rural sites (608/5,470, 11.1%
(10.2–12.0%)) and highest at the urban site (279/1,971, 14.2%
(12.6–15.8%); trend P < 0.001). However, after adjustment for
other risk factors (including maternal age, socio-economic status
and ethnicity; univariable analyses, Supplementary Table 5), the
odds of isolating GBS at the urban site (OR = 0.95 (0.92–0.98))
and rural site (OR = 0.91 (0.88–0.94)) were lower than at the
semi-rural site (P < 0.001; Table 1).
GBS colonization was independently associated with maternal
age, highest in the middle categories (Supplementary Fig. 2;
P = 0.023). It was also associated with parity (≥5 versus 1–4)
(OR = 0.81 (0.70–0.93), P < 0.001), as well as Mijikenda ethnicity
(indigenous population, OR = 0.73 (0.59–0.90), P = 0.003) (Table 1).
GBS colonization was increased in women with higher socio-econ-
omic status (OR = 1.21 (1.13–1.29), P < 0.001) and those who had
contact with cattle (OR = 1.29 (1.17–1.43), P < 0.001). GBS coloniza-
tion was reduced among HIV-infected women and especially in
HIV-infected women taking co-trimoxazole prophylaxis (OR = 0.68
(0.42–1.09); OR = 0.24 (0.14–0.39), P < 0.001), in less well-nourished
mothers (OR = 0.72 (0.60–0.88), P < 0.001) and in women with
obstetric emergencies (OR = 0.85 (0.79–0.92), P < 0.001).
There was evidence that adverse perinatal outcomes (very
preterm delivery, very low birthweight, stillbirth, possible serious
bacterial infection; for deﬁnitions see Supplementary Table 1)
were associated with maternal GBS colonization in multivariable
models in the context of interactions with clinical risk factors for
invasive GBS disease, such as maternal temperature >37.5 °C,
urinary tract infection and prolonged rupture of membranes
>18 h (Fig. 2 and Supplementary Tables 6–9). In contrast, without
Table 1 | Exposures associated with maternal GBS colonization.
No GBS* GBS* Complete cases (N = 3,979) Imputed data (N = 7,967)
Variable N not missing N not missing (%) OR 95%CI† P‡ OR 95%CI† P‡
Site
Rural 479 47 (8.9) 0.80 (0.73–0.88) <0.001 0.91 (0.88–0.94) <0.001
Semi-rural 4,862 608 (11.1) 1 1
Urban 1,692 279 (14.2) 0.96 (0.93–1.00) 0.95 (0.92–0.98)
Age in quartiles (years)§
<21.5 1,674 166 (9.0) 0.77 (0.55–1.15) 0.009 0.80 (0.57–1.15) 0.023
21.5–25.3 1,663 223 (11.8) 1.15 (0.87–1.22) 1.03 (0.88–1.22)
25.4–29.9 1,656 213 (11.4) 1 1
≥30 1,672 186 (10.0) 0.91 (0.78–1.18) 0.96 (0.79–1.18)
Parity
0 2,986 365 (10.9) 1.06 (0.99–1.09) <0.001 1.05 (1.00–1.10) <0.001
1–4 3,550 442 (11.1) 1 1
≥5 1,341 119 (8.2) 0.85 (0.69–0.92) 0.81 (0.70–0.93)
Ethnicity: Mijikenda ||
No 2,226 345 (13.4) 1 0.002 1 0.003
Yes 5,617 578 (9.3) 0.65 (0.60–0.90) 0.73 (0.59–0.90)
Household socio-economic status (quartiles)§
Very low 1,086 96 (8.1) 0.88 (0.66–1.16) <0.001 0.89 (0.66–1.19) <0.001
Low 2,720 294 (9.8) 1 1
Medium 2,123 229 (9.7) 1.00 (0.82–0.92) 0.88 (0.82–0.93)
High 2,038 315 (13.4) 1.24 (1.06–1.30) 1.21 (1.13–1.29)
Mother looks after cattle
No 7,471 873 (10.5) 1 <0.001 1 <0.001
Yes 449 56 (11.1) 1.46 (1.17–1.42) 1.29 (1.17–1.43)
Nutritional status (mid-upper arm circumference in cm§)
≤23.9 1,428 125 (8.0) 0.77 (0.60–0.89) <0.001 0.72 (0.60–0.88) <0.001
24–25.9 2,219 264 (10.6) 1 1
26–27.9 1,662 183 (9.9) 0.80 (0.66–1.07) 0.85 (0.67–1.08)
≥28 2,170 309 (12.5) 1.02 (0.78–1.40) 1.05 (0.79–1.42)
HIV infection
No 7,285 879 (10.8) 1 <0.001 1 <0.001
Yes, no CTX¶ 239 20 (7.7) 1.16 (0.92–1.45) 0.68 (0.42–1.09)
Yes, on CTX¶ 161 5 (3.0) 0.20 (0.14–0.26) 0.24 (0.14–0.39)
Vaginal examination before swab
No 4,952 609 (11.0) 1 0.019 1 0.057
Yes 780 73 (8.6) 0.57 (0.36–0.91) 0.83 (0.70–1.00)
Obstetric complication
No 6,913 823 (10.6) 1 <0.001 1 <0.001
Yes 1,054 111 (9.5) 0.78 (0.70–0.88) 0.85 (0.79–0.92)
*Full details on all variables and numbers for missing variables are given in Supplementary Table 4; †95% conﬁdence intervals are given, based on robust standard errors to account for intracluster correlation
within recruitment sites; ‡P values are derived from the Wald test (imputations combined using Rubin’s rules); §For continuous variables we tested for associations prior to categorization and inclusion in the
model. Where there was nonlinearity, natural cubic splines were used (Supplementary Fig. 2). Data were categorized for ease of presentation and the largest group was used as the reference group; ||Mijikenda
are the indigenous coastal population; ¶CTX, co-trimoxazole prophylaxis.
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GBS colonization there was no evidence that these clinical factors
conferred elevated risk of poor outcomes. There was no evidence
of association of maternal GBS colonization with perinatal
mortality (P = 0.7; Supplementary Table 10), including testing for
an interaction with any risk factor for GBS disease (P = 0.4).
Of 918/934 (98.3%) available and extracted colonizing isolates,
915/934 (98.0%) were of sufﬁcient quality for genomic analysis.
Among colonized mothers, 658/915 (71.9%) GBS isolates were
serotypes Ia, Ib or III, with serotype III being most common
(350/915 (38.3%)). Clonal-complex 17 (CC17) was identiﬁed in
267/915 (29.2%) of GBS-colonized women (Figs 3 and 4 and
Supplementary Table 11). Of these, 265/267 (99.3%) were serotype
III and 2/267 (0.7%) were serotype IV.
The population structure was broadly similar to that in other
parts of the world, with 114/915 (12.5%) CC1, 148/915 (16.2%)
CC10, 268/915 (29.3%) CC17, 173/915 (18.9%) CC19, 208/915
(22.7%) CC23, with 4/915 (0.4%) not belonging to any commonly
described clonal complex. No bovine-associated CC67 (ref. 38)
GBS isolates were identiﬁed. Each of the ﬁve major clonal complexes
was represented at each site (Fig. 4 and Supplementary Table 12),
with no evidence for geographic stratiﬁcation. Within the clonal
complexes, there was considerable diversity, with a total of 43
distinct STs, 18 of which were newly identiﬁed in this study. The
largest number of STs was seen in CC17 (12 STs in total, with 8
newly identiﬁed). The most common STs within CC17 were ST17
(183/268, 68.3%) and ST484 (67/268, 25.0%).
Within GBS-colonized women, risk factors for colonization with
the most virulent clone, CC17, were, in general, the reverse of those
associated with GBS colonization overall (Table 2). Maternal GBS
CC17 was increased in rural sites (OR = 1.26 (1.20–1.31), P < 0.001),
in women of Mijikenda ethnicity (OR = 1.62 (1.43–1.85), P < 0.001)
and in women with HIV infection and women with HIV infection
taking co-trimoxazole (OR = 1.46 (1.11–1.92) and OR= 4.30
(0.59–31.3), P < 0.001). Mothers who had contact with cattle (OR= 0.54
(0.45–0.64), P < 0.001) and were better nourished (OR = 0.79
(0.42–1.49), P < 0.001) were less frequently colonized with CC17,
but this did not hold for ST17 (Supplementary Table 13). For
each of the risk factors, including cattle contact, the corresponding
isolates were dispersed in the phylogeny (Fig. 4), suggesting that the
associations were not driven by speciﬁc sublineages.
Pairwise comparison of all maternal colonizing isolates in
mothers delivering at Kiliﬁ County Hospital (KCH) showed
increased genetic similarity in a small number of mothers who
delivered within seven days of one another, but not according to
household location (Supplementary Fig. 3). Of mothers admitted
fewer than seven days apart in KCH, there were 14/1,013 (1.4%)
pairs from mothers admitted on the same day with 0–4 single
nucleotide variant (SNV) differences, 11/1,967 (0.6%) one day
apart, 2/1,845 (0.1%) two days apart and 2/1,832 (0.1%) six days
apart (P < 0.001). At rural sites, among mothers admitted fewer
than seven days apart, there were 2/124 (1.6%) pairs from
mothers admitted on the same day with 0–4 SNV differences and
2/219 (0.9%) from those admitted one day apart (P = 0.1). At the
urban site, there were 8/987 (0.8%) pairs from mothers admitted
on the same day with 0–4 SNV differences and 3/1,555 (0.2%)
from those admitted one day apart (P < 0.001)22.
GBS in mother–neonatal pairs (surface contamination). We
recruited 830 mother and baby pairs at KCH (Fig. 1 and
Supplementary Table 14). Of these, 104/830 (12.5% (10.4–15.0%))
mothers were colonized with GBS at delivery, and 44/830 (5.3%
(3.9–7.1%)) neonates had GBS isolated from ear, umbilicus or
nose within 6 h of delivery. A total of 30/44 (68.2%) neonates
with surface GBS were born to one of the 104 GBS-colonized
mothers, and 14/44 (31.8%) were born to one of the 726 mothers
without colonizing GBS detected (of these, 2/14 (14.3%) were
born by caesarean section). Odds of neonatal surface GBS were high
with maternal GBS colonization (OR = 20.6 (10.5–40.6), P < 0.001).
Pairwise SNV comparisons between maternal and newborn
isolates showed a clear bimodal distribution: 26/30 (86.7%) pairs
differed by ≤4 SNVs (all pairs the same ST and serotype),
presumably representing vertical transmission, and 4/30 (13.3%)
Outcome: Very preterm birth
Exposure: Maternal fever
Outcome: Very low birthweight 
Exposure: Maternal fever
Outcome: Stillbirth 
Exposure: Maternal urinary tract 
infection
Outcome: Possible serious 
bacterial infection** 
Exposure: Prolonged rupture of 
membranes
{
{
{
{
GBS positive
GBS negative
OR (presence vs absence of exposure)
0.1 1 10 100
P = 0.019
P < 0.001
P = 0.104
P = 0.104
Figure 2 | Interaction of risk factors at delivery with maternal GBS colonization associated with adverse newborn outcomes. Interactions between
maternal risk factors at delivery (maternal fever, maternal urinary tract infection, prolonged rupture of membranes) and adverse perinatal outcomes (very
preterm birth, very low birthweight, stillbirth, possible serious bacterial infection), in the presence and absence of maternal GBS colonization. Odds ratios are
given for maternal exposures and associated perinatal outcome (listed vertically) with 95% conﬁdence intervals illustrated with error bars for the odds ratio
in each case. Interactions were included in multivariable models if there was evidence of interaction at the P < 0.1 level in univariable analyses. P values given
here are for interaction tests in imputed multivariable models (details for all models are provided in Supplementary Tables 5–9). **Possible serious bacterial
infection (pSBI) is deﬁned in Supplementary Table 1; this is a clinical diagnosis used to guide empiric treatment of neonates for possible serious bacterial
infections in resource-poor settings.
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pairs were highly divergent (>9,000 SNVs, with different STs and
different serotypes) (Fig. 4). Combining all pairs with ≤4 SNVs,
the SNVs were dispersed throughout the genome, with no gene
represented more than once. There were 7/44 (15.9%) neonates
with surface GBS after delivery by caesarean section (5 of their
mothers had GBS detected; 3/5 had 0 SNV differences, 1/5 had
1 SNV and 1/5 had 9,673 SNVs).
Stillbirth. There were 278 stillbirths during the nested case-control
study (278/4,394 (6.3%) all births). We sampled cord blood in
149/278 (53.6%; 94/149 (63.1%) intra-partum, 55/149 (36.9%)
ante-partum stillbirths), 104 also had a lung aspirate, and
34/278 (12.2%) had a lung aspirate sample only. In total, 183/278
(65.8%) stillbirths were sampled, plus 330 live-birth cord blood
controls (Fig. 1).
GBS was isolated from 4/183 (2.2% (95%CI 0.6–5.5)) stillbirths
(3/149 cord blood samples, 2/138 lung aspirates; one stillbirth had
GBS isolated from both), two ante-partum (36 and 39 weeks
gestation) and two intra-partum (35 and 39 weeks). The overall
minimum incidence of GBS-associated stillbirth (cord blood or
lung aspirate) was 0.91 (0.3–2.3)/1,000 births. Compared to live-
born controls (GBS isolated from 1/330 (0.3%)), GBS was isolated
more frequently from cord blood in stillbirths (OR= 6.8 (0.7–65.5),
P = 0.09) and, in a multinomial model, ante-partum stillbirths
(OR = 12.4 (1.1–139.3)) and intra-partum stillbirths (OR = 3.5
(0.2–57.1) exact P = 0.055). Serotype data were available from
three stillbirths (two were serotype V and one serotype III).
There were 2/4 GBS-associated stillbirths born to GBS colonized
mothers (2/2 pairs differed by 0 SNVs, all ST1, serotype V). One
mother was not colonized, and one was not tested. The risk ratio
for GBS-associated stillbirth in GBS-colonized versus non-colonized
mothers was 7.6 (1.1–52.6, P = 0.016).
Neonatal disease. Eighty-two neonates with invasive GBS disease
were admitted to KCH (1998–2013, Fig. 1), of which 36/82
(43.9%) and 43/82 (52.4%) were associated with EOD and LOD,
respectively (three unknown). Case fatality was highest in EOD
(17/36 (47.2%)), despite treatment, particularly for those
diagnosed within <24 h of birth (11/18 (61.1%)). In patients with
LOD, 5/43 (11.6%) died. Most GBS EOD cases (52/82 (63.4%))
were male and 25/82 (30.5%) weighed <2,500 g at admission
(Supplementary Table 15). Sepsis without focus was predominant
in EOD (33/36 (91.6%)), with meningitis (+/− sepsis) being more
common in LOD (21/43 (48.8%)) (Fig. 3). Gestational age was
not routinely available from previous clinical surveillance data, but
there were ﬁve EOD cases with gestations of 36, 36, 37, 37 and
40 weeks born at the time of the prospective cohort study (versus
a median of 38 (interquartile range (IQR) 36–40) overall in the
prospective cohort).
EOD incidence among deliveries at KCH during the cohort study
(2011–2013) was 0.76 (0.25–1.77)/1,000 live births. Including only
residents in the Kiliﬁ Health and Demographic Surveillance
System (KHDSS) population (1998–2013), the (minimum)
population-based incidence of neonatal GBS disease was 0.34
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Figure 3 | GBS types colonizing mothers and causing disease. a, Invasive neonatal GBS disease cases decrease after the ﬁrst few days of birth in KCH
neonatal admissions (1998–2013) and serotype III causes an increasing proportion of disease. b, The clinical infection syndrome is predominantly sepsis in
the ﬁrst few days after birth in neonates admitted with invasive GBS disease to KCH (1998–2013), with increasing numbers of neonates admitted with
meningitis with or without sepsis later in the neonatal period. c, Percentage of different serotypes in GBS isolates from maternal colonization, early onset
disease (EOD) and late onset disease (LOD) in neonates shows a stepwise increase in serotype III from maternal colonization to EOD and LOD.
d, Percentage of different clonal complexes in GBS isolates from maternal colonization, neonatal sepsis and neonatal meningitis (+/− sepsis) shows the
increasing dominance of CC17 in neonatal disease, particularly in neonatal meningitis.
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(0.24–0.46)/1,000 live births: EOD in 0.13 (0.07–0.21)/1,000 live
births and LOD in 0.21 (0.14–0.31)/1,000 live births, with no
evidence of a trend over the study period (Supplementary Fig. 4).
There were 73/82 (89.0%) neonates with available invasive
isolates that were extracted, and all were of sufﬁcient quality for
inclusion in the ﬁnal analysis. Serotypes Ia/Ib/III caused 71/73
(97.3%) of EOD and LOD, and serotypes Ia/Ib/II/III caused 72/73
(98.6%) of cases. Serotype III predominated in both EOD (18/30
(60.0%)) and LOD (36/40 (90.0%); P = 0.003, χ2 test for trend).
These isolates were all CC17, except one CC19 isolate (Fig. 4).
Serotype III was the almost universal cause of meningitis (22/23
(95.7%) cases), of which 21/22 (95.4%) were CC17 (Fig. 3 and
Supplementary Table 16). Isolates were all susceptible to penicillin
and 61/76 (80.3%) were susceptible to co-trimoxazole.
Three of the ﬁve neonates with EOD born at KCH (2011–2013)
were born to GBS-colonized mothers (1/3 pairs differed by 0 SNVs
(both ST17, serotype III), 1/3 pairs by 88 SNVs (one ST17, one
ST484, both serotype III) and 1/3 pairs by 1,002 SNVs (both
ST17, serotype III), with a risk ratio (RR) for EOD for
GBS-colonized versus non-colonized mothers of 11.8 (2.0–70.3),
P < 0.001). For all perinatal GBS disease (EOD or stillbirth),
RR = 13.1 (3.1–54.8, P < 0.001).
Discussion
GBS is an important cause of stillbirth and neonatal disease in
Kenya. The incidence of stillbirth was comparable to EOD in hospi-
tal births (0.91 (0.25–2.3)/1,000 births and 0.76 (0.25–1.77)/1,000
live births, respectively). These incidences are all underestimates,
with samples not taken from all stillbirths and insensitivity in cul-
tures, particularly if intrapartum antibiotics were given. The much
lower population-based incidence of EOD (0.13 (0.07–0.21)/1,000
live births) suggests recruitment bias with under ascertainment of
cases in the community, or in outpatient settings, due to rapid
case fatality after delivery and limited access to care. This is sup-
ported by the higher proportion of LOD, which is the reverse of
the ratio of GBS disease typically seen in high-income countries23.
Although it could be argued that facility delivery is a risk factor
for EOD (if there was in-hospital maternal GBS acquisition), we
found very limited evidence of horizontal transmission in facilities,
with few genetically near-identical pairs (0–4 SNVs, threshold
determined empirically from a newborn surface contamination
study) in mothers admitted fewer than seven days of each other.
However, there may be true differences in the incidences of both
GBS-associated stillbirth and neonatal GBS disease in sSA, which
are neither explained by the study design nor by other methodologi-
cal limitations. The incidences of neonatal GBS disease recently
reported in urban South Africa29 and Malawi23 are high and could
be due to differences in maternal GBS colonization prevalence, con-
sistent with our ﬁnding of a higher prevalence of maternal GBS
colonization in urban compared to semi-rural and rural residents.
This association was explained by variables describing an improved
socio-economic status and other factors associated with improved
health, such as better nutritional status, being in middle age cat-
egories and a lower parity, both in the complete-case analyses and
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Figure 4 | Phylogenetic reconstructions of GBS isolates. Maximum likelihood phylogenies, with recombinant regions removed, are shown separately for
each clonal complex. Background shading indicates ST17 isolates within CC17. Serotypes are illustrated for each clonal complex in the innermost circle. The
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using multiple imputation. Although our study includes impover-
ished populations, the pattern of risk factors identiﬁed is consistent
with recent studies in high-income countries reporting increased
maternal GBS colonization with higher education14,16 and higher
income16. The reasons for this are unclear, but are probably
related to changes in the maternal microbiome, with different
community states reported39.
The use of prophylactic co-trimoxazole among HIV-infected
women had a clear negative association with GBS colonization.
Previously reported conﬂicting ﬁndings17,18 may depend on the fre-
quency of antimicrobial use (and provision of anti-retroviral
therapy). In contrast, neonatal GBS disease is increased with HIV
exposure40, with reduced maternal GBS capsular antibody in HIV-1
infection41,42 and/or because, as shown here, the most virulent
clone, CC17, is more frequently found in HIV-infected GBS
colonized women, compared to other non-CC17 types. A number
of virulence factors (adhesins, invasins and immune evasins) have
been associated with an increased ability of GBS to colonize and
cause disease43, with the more homogeneous CC17 having acquired
its own set of virulence genes38 and increased ability to form
bioﬁlms in acidic conditions44.
We observed an association between cattle contact and maternal
GBS colonization, but no bovine-associated CC67 isolates were
identiﬁed, and the isolates from women with cattle contact were
from a variety of lineages representing all major CCs. Little is
known about bovine GBS populations in Kenya, and it is possible
that the human and bovine populations are similar, thus leading to
the association between cattle contact and maternal GBS colonization
from genuine transmission, as suggested elsewhere45. Alternatively,
women who look after cattle may be of a higher socio-economic
status, and thus the association could be due to residual confounding.
The overall GBS population structure outlined here is similar to
that found in previous studies from a variety of geographic locations,
supporting the notion of recent global dissemination of relatively
few clones32. Within this study, we found no evidence for geo-
graphic clustering of related isolates, both at the level of sampling
location (Fig. 4) and distance between households (Supplementary
Fig. 3), further suggesting the rapid geographic dispersal of GBS.
However, in contrast to a previous study from Africa35, we found
no CC26 isolates, suggesting that this lineage may be geographically
restricted. Furthermore, we found a large number of ST484 isolates,
67/915 (7.3%) of the total and 67/268 (25.0%) of CC17. This lineage
has previously been reported in only a single study, also from
Kenya46. We also identiﬁed three novel STs that represent single-
locus variants of ST484. Taken together, it is possible that ST484
originated in or near Kenya, with relatively little geographic disper-
sal. Alternatively, there may be a lack of GBS sampling in other
locations where ST484 is present.
Prevention strategies in resource-rich settings focus on reducing
EOD through IAP using either microbiological or risk-factor
screening to identify at-risk mothers7. Both strategies would be chal-
lenging in resource-poor settings. Of interest, when comparing
these strategies, however, is the fact that associations with adverse
perinatal outcomes were only detected through interactions
between maternal GBS colonization and clinical risk factors. This
supports a mechanism of action whereby colonizing maternal
Table 2 | Exposures associated with maternal GBS colonization with CC17.
GBS Univariable complete cases (N = 914) Multivariable complete cases (N = 728)
Variable Not CC17 N CC17 (%) OR 95%CI* P† OR 95%CI* P†
Site
Rural 33 13 28.3 0.85 (0.43–1.65) 0.072 1.26 (1.20–1.31) <0.001
Semi-rural 403 187 31.7 1 1
Urban 211 67 24.1 0.68 (0.49–0.95) 0.98 (0.79–1.04)
Age in quartiles (years)‡
<21.5 115 49 29.9 1.16 (1.07–1.27) 0.2 1.21 (0.88–1.67) 0.004
21.5–25.3 156 60 27.8 1.05 (0.92–1.21) 0.88 (0.77–1.01)
25.4–29.9 153 56 26.8 1 1
≥30 130 51 28.2 1.07 (0.85–1.35) 1.06 (0.74–1.51)
Parity
0 257 98 27.6 0.86 (0.49–1.51) 0.4 0.75 (0.35–1.55) <0.001
1 to 5 301 133 30.6 1 1
≥5 83 35 29.7 0.95 (0.83–1.10) 0.68 (0.60–0.80)
Ethnicity: Mijikenda§
No 262 79 23.2 1 <0.001 1 <0.001
Yes 379 183 32.6 1.60 (1.52–1.69) 1.62 (1.43–1.85)
Household socio-economic status‡ (quartiles)
Very low 71 25 26.0 0.61 (0.48–0.80) <0.001
Low 192 95 33.1 1
Medium 155 69 30.8 1.21 (0.82–1.80)
High 229 78 25.4 0.69 (0.41–1.15)
Mother looks after cattle
No 598 255 29.9 1 <0.001 1 <0.001
Yes 44 12 21.4 0.64 (0.58–0.70) 0.54 (0.45–0.64)
Nutritional status (mid-upper arm circumference in cm‡)
≤23.9 81 41 33.6 1.19 (0.57–2.56) 0.0042 1.05 (0.39–2.83) <0.001
24–25.9 181 77 29.8 1 1
26–27.9 130 48 27.0 0.87 (0.56–1.35) 0.73 (0.42–1.28)
≥28 219 85 28.0 0.91 (0.57–1.46) 0.79 (0.42–1.49)
HIV infection
No 608 251 29.2 1 <0.001 1 <0.001
Yes, no CTX|| 13 7 35.0 1.30 (1.21–1.40) 1.46 (1.11–1.92)
Yes, on CTX|| 2 3 60.0 3.63 (1.58–8.34) 4.30 (0.59–31.3)
*95% conﬁdence intervals are given, based on robust standard errors to account for intracluster correlation within recruitment sites; †P values are derived from theWald test; ‡For continuous variables we tested
for associations prior to categorization and inclusion in the model. Where there was nonlinearity, natural cubic splines were used (Supplementary Fig. 2). Data were categorized for ease of presentation and the
largest group was used as the reference group; §Mijikenda are the indigenous coastal population; ||CTX, co-trimoxazole prophylaxis.
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GBS ascends, leading to chorioamnionitis (intra-amniotic infection)
and fever in a small proportion of women, leading to poor perinatal
outcomes. Neither maternal GBS colonization without signs of
infection nor maternal fever without GBS colonization increased
the risk of adverse perinatal outcomes. Thus, either approach
(microbiological or risk-factor screening) will target far larger
numbers than those actually at risk. Any direct association
between maternal GBS colonization and adverse outcomes may
also be diluted by the many other causes of adverse perinatal out-
comes and by misclassiﬁcation (for example, uncertainty over the
date of the last menstrual period to determine gestation), which
may explain some of the conﬂicts in ﬁndings of studies assessing
the contribution of GBS to preterm birth4.
We demonstrated the vertical transmission of maternal GBS
colonization in maternal–newborn dyads, for both surface contami-
nation (including cases of emergency caesarean section) and peri-
natal disease. Genetically divergent maternal–newborn dyads may
reﬂect unsampled variation in the mother, as only a single colony
was sequenced in each case. Although adaptive mutations associated
with disease progression have been reported elsewhere from a com-
parison of mother–newborn pairs47, we were unable to ﬁnd evidence
for this in the current study, as all pairs involving invasive isolates
were either genetically identical (0 SNVs) or divergent enough to
argue against this. The ﬁndings show that GBS infection occurs
before delivery, supporting the need for IAP to be administered
before delivery to be effective and showing why antisepsis in
active labour (for example, by using vaginal chlorhexidine wipes)
is ineffective in reducing neonatal EOD8. The ﬁnding of 14/44
(31.8%) newborns with surface GBS contamination where maternal
GBS colonization was not identiﬁed suggests insensitivity of
maternal recto–vaginal screening, despite the consistent use of
broth-enrichment and blood agar to maximize sensitivity. This is
a higher percentage than found in a recent study in The Gambia
(40/186 (21.5%))48, but this study excluded mothers at high risk
for pregnancy complications. As is found with repeat vaginal exam-
inations, as seen here and reported elsewhere49, complicated deliv-
eries (obstetric emergencies) probably decrease GBS sampling
sensitivity, through antisepsis measures or mechanical removal.
With limitations in the clinical beneﬁt of IAP in terms of reducing
stillbirth and LOD, as well as challenges in its effective implemen-
tation to reduce EOD in sSA, maternal vaccination is an attractive
strategy for prevention. The most advanced vaccine (which has
completed phase 2 trials) is trivalent (Ia/Ib/III), but plans exist to
advance a pentavalent vaccine10. If this includes the most common
disease-causing serotypes worldwide (Ia/Ib/II/III/V), it will cover
almost all (72/73 (98.7%)) of the serotypes causing invasive disease
in this study. However, importantly for vaccine development, and
in line with other reports50, we identiﬁed capsular switching to sero-
type IV in two isolates within CC17, suggesting that consideration of
the inclusion of serotype IV is warranted.
GBS is an important, potentially preventable, cause of stillbirth and
neonatal death in coastal Kenya. Maternal GBS colonization increases
with urbanization and higher socio-economic status, and is likely to
increase with development. GBS neonatal disease in population-
based studies is markedly under-ascertained as a result of rapid case
fatality after birth and limited access to care. The burden of early neo-
natal disease is likely equalled by the burden of GBS-associated still-
birth. Maternal GBS vaccination is a key opportunity to reduce
stillbirth and neonatal death in this high-burden region.
Methods
Study design. The study design included a prospective cohort from rural, semi-rural
and urban sites, a nested case–control study in the semi-rural site, and analysis of the
surveillance of neonatal disease at the semi-rural site (Fig. 1).
Prospective cohort study. In a prospective cohort study (2011–2013), we assessed the
prevalence and risk factors for maternal GBS colonization at delivery, and the
perinatal outcomes at delivery (stillbirth, gestational age, birthweight, possible
serious bacterial infection and perinatal death).
Nested case–control study. The investigation of stillbirth was undertaken with a
nested case–control study. Cord blood cultures were taken at delivery from the
stillbirth and from the next two subsequent admissions that were live born (case:
controls = 1:2). Lung aspirates were taken from stillbirths only, by a study clinician
attending within 4 h of the stillbirth.
Surveillance of neonatal invasive bacterial disease. Neonatal disease was quantiﬁed
using systematic clinical and microbiological surveillance data (1998–2013 at KCH)
within the KHDSS area, giving accurate population and birth denominators (see
‘Study sites’)51.
Study sites. The studies were conducted at Coast Provincial General Hospital,
Mombasa (CPGH; urban location, ∼12,000 deliveries per year, comprehensive
obstetric care); at Kiliﬁ County Hospital (KCH; semi-rural, ∼3,000 deliveries per
year, comprehensive obstetric care); at Bamba sub-district hospital (rural, ∼600
deliveries a year, basic obstetric care) and Ganze health facility (rural, ∼400
deliveries a year, basic obstetric care).
Part of Kiliﬁ County is included in detailed health and demographic surveillance
(KHDSS)51, from which accurate population data are available from 2004. KCH is
the main district hospital serving this population, so incidence estimates for
residents seeking healthcare at KCH can be made with the KHDSS population as the
denominator. We used prospectively collected data on live births from the regular
re-enumerations of the KHDSS population, and used the estimated slope from a
regression to estimate the number of births before the start of KHDSS.
Study population. Prospective cohort study. We included all women admitted for
delivery at study sites at designated times who gave written informed consent,
without additional exclusion criteria. We planned to recruit over one calendar year
(to allow for seasonality), but extended the enrolment to meet sample size
requirements (Supplementary Table 3) because national strikes closed government
health facilities twice during the study. Recruitment was performed at CPGH for
48 h each week (1 April 2012 to 31 July 2013), at Bamba and Ganze for six days
each week (1 July 2012 to 31 July 2013) and at KCH every day (1 August 2011 to
31 July 2013), including additional studies of neonatal surface contamination
(1 May 2012 to 31 July 2013).
Nested case–control study. We included all stillbirths delivered in KCH and the next
two consecutive live births (1 May 2012 to 1 October 2013).
Surveillance of neonatal invasive bacterial disease.We included all neonates admitted
to KCH (1 August 1998 to 1 October 2013).
Sampling and laboratory methods. Prospective cohort study.We took recto–vaginal
swabs during routine vaginal examination at admission for delivery, when possible
before rupture of membranes. A small cotton swab was used to wipe the lower third
of the vaginal mucosa and then the inside surface mucosa of the anus52, according to
standard procedures. Neonatal surface swabs (to assess surface contamination)
included the external ear, nares and umbilicus. Swabs were placed into Amies
transport medium with charcoal53, refrigerated, transported in cool containers53 to
the research laboratory (participating in the UK National External Quality
Assessment Service) and processed by standard protocols (including enrichment
(Lim broth) and subculture onto blood agar). Isolates with GBS morphology were
Christie Atkins Munch-Petersen (CAMP) tested and deﬁnitive grouping done using
a Streptococcal grouping latex agglutination kit
(PRO-LAB Diagnostics).
Nested case–control study. For stillbirths and live-born controls, we sampled cord
blood at delivery after double clamping the cord if necessary and cleaning with 70%
ethanol. We processed cord blood cultures using an automated culture system
(BACTEC 9050, Becton Dickinson). Lung aspirate samples (stillbirths only) were
taken with a sterile technique by aspirating the lung within 4 h of delivery. We
examined lung aspirates with microscopy and cultured using standard methods
within 30 min of sampling, or if a delay was unavoidable they were stored at 2–8 °C
for up to 8 h.
Surveillance of neonatal invasive bacterial disease. For all neonatal admissions
(1998–2013) at KCH, peripheral blood was sampled on admission for culture, before
neonatal antibiotic treatment (during 2011–2013, peri-partum maternal antibiotics
were documented in 36/5,430 (0.7%) of deliveries in KCH), and we carried out
lumbar puncture when clinically indicated. We tested the isolates for antimicrobial
susceptibility to penicillin and co-trimoxazole (British Society for Antimicrobial
Chemotherapy). Blood cultures were processed using an automated culture system
(BACTEC 9050). Cerebrospinal ﬂuid was tested as described elsewhere26.
Molecular methods. DNA extraction, Illumina sequencing (Hiseq Technology)
and raw read processing were carried out using standard methods starting from a
ARTICLES NATURE MICROBIOLOGY DOI: 10.1038/NMICROBIOL.2016.67
NATURE MICROBIOLOGY | VOL 1 | JULY 2016 | www.nature.com/naturemicrobiology8
© 2016 Macmillan Publishers Limited. All rights reserved
single GBS colony. GBS isolates were frozen in 1 ml vials and stored at –80 °C
before subculture on a Columbia blood agar plate for 24–48 h, followed by
DNA extraction from a single colony using a commercial kit (QuickGene,
Fujiﬁlm). High-throughput sequencing was undertaken at the Wellcome Trust
Centre for Human Genetics (Oxford University) using HiSeq2500, generating
150 base-paired end reads. De novo assembly, mapping and variant calling
were performed as described previously54, except that mapping was to
S. agalactiae reference genome 2603 V/R (NC_004116.1). Sequence quality
was assessed using various metrics (per cent reads mapped to the reference
genome, per cent reference positions called, contig number, total contig
length). Sequence data showing poor quality metrics were excluded from
further analysis, and where practicable the corresponding samples were
re-isolated, re-grouped and re-sequenced (if re-grouping conﬁrmed the
isolate as GBS).
We allocated serotypes on the basis of BLASTn comparisons by assessing
the sequence similarity of de novo assemblies with the capsular locus regions
of each of the ten known GBS serotypes. We validated this method internally
(kappa = 0.92)55. STs were also assigned in silico using BLASTn with de novo
assemblies. Novel STs were submitted to pubmlst.org for assignment.
Phylogenetic analysis was performed separately for each clonal complex using
RAxML version 8.1.16, with an alignment consisting of all variable sites from
mapping to the 2603 V/R reference, padded to the length of the reference with
invariant sites of the same GC content as the original data. Recombination was
detected using ClonalFrameML56 and we present the resultant phylogenies with
recombinant regions removed. To partition the isolates according to previously
described clonal complexes, we ﬁrst reconstructed a single RAxML phylogeny
with all isolates. The resulting tree was then visually partitioned on long, deep
branches, which effectively corresponded to previously described clonal
complexes, but enabled us to include all STs. We therefore used this partitioning
as our deﬁnition of the clonal complexes. Using this deﬁnition, each ST
belongs to a single clonal complex and each clonal complex is monophyletic
(Supplementary Fig. 6), indicating that partitioning by clonal complex remains
appropriate when whole-genome data are taken into account.
Pairwise comparison of SNV differences from mapped data was used to examine
maternal and newborn paired GBS isolates, and possible transmission of GBS
between mothers was investigated via these differences and epidemiological links in
time and place (through delivery in KCH) or residence (distance between household
locations in KHDSS).
Statistical analysis.We used Stata (version 13.1) for statistical analyses. We used the
ﬁrst principal component from a set of household assets as a proxy for socio-
economic status (SES)57. Multiple imputation with chained equations (Stata mi) was
used to impute missing data on potential risk factors (<15% per variable;
50 imputations). Continuous variables were checked for normality and
transformation was not required. We used natural cubic splines to allow for
nonlinearity in variable effects in imputation models. Imputations were done
separately by maternal GBS status so that interactions could be examined in the
analyses of adverse newborn outcomes. The same imputation was used for both
analyses; by imputing separately for GBS colonization there are fewer assumptions
than if it was ﬁtted as a covariate (this allows variances of continuous imputed
variables to differ according to GBS colonization and the associations between two
imputed variables can be stronger in one group).
We built multivariable logistic regression models using complete-case and
imputed data sets (combined using Rubin’s rules) to examine risk factors for
maternal GBS colonization using robust variances reﬂecting clustering by site. We
included nonlinearity in continuous variables via natural cubic splines, with factors
categorized at quartiles for the presentation of ﬁnal models. Risk factors with P < 0.1
in univariable models were included in a multivariable model, and ﬁnal independent
predictors were identiﬁed using backwards elimination (exit P > 0.1). We assessed
whether risk factors for maternal GBS colonization were associated with ST17 and
CC17 colonization in mothers who were GBS colonized using the same process, for
complete cases only.
We used the imputed data set in multivariable regression analyses to examine
whether maternal GBS colonization was associated with gestational length,
birthweight, possible serious bacterial infection, stillbirth or perinatal mortality. We
included pre-speciﬁed confounders (age, parity, sex (of newborn), maternal
education, SES, nutritional status, HIV status, obstetric complication and multiple
delivery) and tested for interaction with GBS colonization from prolonged rupture of
membranes (PROM, >18 h), maternal fever (>37.5 °C) or urinary tract infection
(leukocytes and nitrites present). We included these terms in multivariable models if
there was evidence of interaction at the P < 0.1 level.
We estimated the odds of isolating GBS from cord blood in all stillbirths, then
ante-partum and intra-partum stillbirths, compared to live births. We estimated the
incidence of GBS-associated stillbirth and neonatal disease using denominators of
facility births and community births, for residents of KHDSS51.
Ethics. The study protocol was approved by KEMRI Ethical Review Committee
(SSC/ERC 2030) and the Oxford Tropical Research Ethics Committee (53-11)
(clinicaltrials.gov NCT01757041).
Accession codes. Sequence data have been submitted to the NCBI Sequence Read
Archive under BioProject PRJNA315969. Individual accession numbers are
provided in Supplementary Table 17 (BioProject PRJNA315969).
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